Skip to main content

Table 2 Relapse rate in mixed systemic/non-systemic JIA patients after withdrawal of bDMARD

From: Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors

Main author

Baszis

Remesal

Postępski

Simonini

Romano

Vidqvist

Pratsidou-Gertsi & Trachana

Anink

Otten

Su

Tynjälä

Klotsche

[ref]

[32]

[33]

[34]

[35]

[36]

[37]

[38, 39]

[40]

[41]

[42]

[43]

[20]

n=

136

26

39

135

27

19

13

18

39

30

27

209

% of soJIA patients in withdrawl-group

unknown

8

18

9

unknown

unknown

27e

unknown

unknown

10

unknown

unknown

% of soJIA patients in entire studya

12

NA

NA

NA

17

1

NA

28

18

NA

6

6

Medication type

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

Etanercept

 

Adalimumab

  

Adalimumab

Adalimumab

Adalimumab

    

Infliximab

 
 

Infliximab

  

Infliximab

Infliximab

Infliximab

      
    

d

        

Time in inactive disease, months

 

at least 6c

 

at least 6

at least 6

unknown

at least 6

unknown

unknown

at least 6

unknown

unknown

 mean (range)

  

21.3 (4-42)

         

 median (range)

6.1 (0-67.9)

           

Follow up duration, months

b

   

unknown

unknown

at least 12

   

unknown

 

 mean (range)

 

21 (5-44.5)

25.4 (16-60)

6 (3-109)

   

(10-78)

13.4f

26

 

46.8g

% relapse after withdrawal

68%

69.2%

69.2%

75.6%

48.1%

unknown

84.6%

77.8%

38.5%

56.7%

55.6%

77%

Time to relapse, months

            

 mean (range)

5.8 (0.6-15.9)

14.2 (1-60)

  

18 (0-108)

      

 median (range)

    

6.6 (2.4-28.6)

 

3 (1-15)

9 (1-69)

    

% relapse after 3 months

25%

           

% relapse after 6 months

50%

50%

38.5%

         

% relapse after 12 months

68%

61%

 

68.9%

        
  1. NA not applicable
  2. aIn case the portion of sJIA patients in the withdrawl study was not known
  3. bfollow up was > 12 months in 71% of patients
  4. c24 out of 26 were in clinical remission on medication
  5. das well as anakinra (in 7 patients), rituximab and abatacept (both in 1 patient)
  6. eIn 2 patients JIA subtype is unknown [43]
  7. fIQ 5.3 - 24.7
  8. gSD 3.5 years